Research graph
References from Phase 1 trial of venetoclax with cladribine, cytarabine, G-CSF, and mitoxantrone for AML and high-grade myeloid neoplasm. Local targets link to admitted publications; unresolved targets remain external evidence.
Phase 1/2 trial of GCLAM with dose-escalated mitoxantrone for newly diagnosed AML or other high-grade myeloid neoplasms
10.1038/s41375-018-0135-8 · 2018 · External reference
Phase I/II trial of cladribine, high-dose cytarabine, mitoxantrone, and G-CSF with dose-escalated mitoxantrone for relapsed/refractory acute myeloid leukemia and other high-grade myeloid neoplasms
10.3324/haematol.2018.204792 · 2019 · External reference
Venetoclax combined with decitabine or azacitidine in treatment-naive, elderly patients with acute myeloid leukemia
10.1182/blood-2018-08-868752 · 2019 · External reference
Azacitidine and venetoclax in previously untreated acute myeloid leukemia
10.1056/nejmoa2012971 · 2020 · External reference
Venetoclax combined with FLAG-IDA induction and consolidation in newly diagnosed acute myeloid leukemia
10.1002/ajh.26601 · 2022 · External reference
Venetoclax plus intensive chemotherapy with cladribine, idarubicin, and cytarabine in patients with newly diagnosed acute myeloid leukaemia or high-risk myelodysplastic syndrome: a cohort from a single-centre, single-arm, phase 2 trial
10.1016/s2352-3026(21)00192-7 · 2021 · External reference
Safety and efficacy of venetoclax plus “7 + 3” chemotherapy in newly diagnosed AML [abstract]
2023 · External reference
Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel
10.1182/blood-2016-08-733196 · 2017 · External reference
Distinguishing AML from MDS: a fixed blast percentage may no longer be optimal
10.1182/blood.2021011304 · 2022 · External reference
Prediction of early death after induction therapy for newly diagnosed acute myeloid leukemia with pretreatment risk scores: a novel paradigm for treatment assignment
10.1200/jco.2011.35.7525 · 2011 · External reference
Duration of cytopenias with concomitant venetoclax and azole antifungals in acute myeloid leukemia
10.1002/cncr.33508 · 2021 · External reference
Bayesian optimal interval design: a simple and well-performing design for phase I oncology trials
10.1158/1078-0432.ccr-16-0592 · 2016 · External reference
Early hospital discharge after intensive induction chemotherapy for adults with acute myeloid leukemia or other high-grade myeloid neoplasm
10.1038/s41375-019-0586-6 · 2020 · External reference
Diagnosis and management of AML in adults: 2022 recommendations from an international expert panel on behalf of the ELN
10.1182/blood.2022016867 · 2022 · External reference
Survival of patients with acute myeloid leukemia relapsing after allogeneic hematopoietic cell transplantation: a Center for International Blood and Marrow Transplant Research study
10.1016/j.bbmt.2014.11.007 · 2015 · External reference
Venetoclax combined with FLAG-IDA induction and consolidation in newly diagnosed and relapsed or refractory acute myeloid leukemia
10.1200/jco.20.03736 · 2021 · External reference
Comparison of mold active triazoles as primary antifungal prophylaxis in patients with newly diagnosed acute myeloid leukemia in the era of molecularly targeted therapies
10.1093/cid/ciac230 · 2022 · External reference
